Transfection of tumor-infiltrating T cells with mRNA encoding CXCR2

Methods in Molecular Biology

Volumn 1428, Issue , 2016, Pages 261-276

  Idorn, Manja ^a   Straten, Per Thor ^a   Svane, Inge Marie ^a   Met, Özcan ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer immunotherapy; Chemokine receptor; mRNA transfection; Tumor homing; Tumor infiltrating lymphocytes (TILs)

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; MESSENGER RNA;

ADOPTIVE TRANSFER; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTROPORATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NEOPLASM; RNA SYNTHESIS; T LYMPHOCYTE; TRANSIENT EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; TUMOR CELL CULTURE;

ADOPTIVE TRANSFER; ELECTROPORATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECEPTORS, INTERLEUKIN-8B; RNA, MESSENGER; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84990194133     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3625-0_17     Document Type: Chapter

References (25)

1. Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-4557
2. Besser MJ, Shapira-Frommer R, Itzhaki O et al (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19:4792-4800
3. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
4. Donia M, Larsen SM, Met Ö, Svane IM (2014) Simplified protocol for clinical-grade tumorinfiltrating lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy 16:1117-1120
5. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101(Suppl):14639-14645
6. Donia M, Hansen M, Sendrup SL et al (2013) Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol 133:545-552
7. Koya RC, Mok S, Otte N et al (2012) BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 72:3928-3937
8. Li Y, Liu S, Hernandez J et al (2010) MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 184:452-465
9. Chacon JA, Wu RC, Sukhumalchandra P et al (2013) Co-stimulation through 4-1BB/ CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. doi:10.1371/journal.pone.0060031
10. Pockaj BA, Sherry RM, Wei JP et al (1994) Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73:1731-1737
11. Peng W, Ye Y, Rabinovich BA et al (2010) Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 16:5458-5468
12. Moon EK, Carpenito C, Sun J et al (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 17:4719-4730
13. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
14. Waugh DJJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735-6741
15. June CH, Blazar BR, Riley JL (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9:704-716
16. Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733
17. Cameron BJ, Gerry AB, Dukes J, et al. (2013) Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 5:197ra103.
18. Rabinovich PM, Weissman SM (2013) Cell engineering with synthetic messenger RNA. Methods Mol Biol 969:3-28
19. Met O, Balslev E, Flyger H, Svane IM (2011) High immunogenic potential of p53 mRNAtransfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat 125:395-406
20. Yokoyama WM, Thompson ML, Ehrhardt RO (2012) Cryopreservation and thawing of cells. Curr Protoc Immunol. doi:10.1002/0471142735.ima03gs99
21. Dudley ME, Wunderlich JR, Shelton TE et al (2008) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342
22. Donia M, Junker N, Ellebaek E et al (2011) Characterization and comparison of “Standard” and “Young” tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol 157-167
23. Schaft N, Dörrie J, Müller I et al (2006) A new way to generate cytolytic tumor-specific T cells: Electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 55:1132-1141
24. Zhao Y, Zheng Z, Cohen CJ et al (2006) High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 13:151-159
25. Teissié J, Rols MP (1993) An experimental evaluation of the critical potential difference inducing cell membrane electropermeabilization. Biophys J 65:409-413